Why the study?
Does the implantable cardioverter defibrillator (ICD) prevent sudden cardiac death in high-risk patients?
Does the implantable cardioverter defibrillator (ICD) prevent sudden cardiac death in high-risk patients?
This review summarizes the role of ICDs in the primary prevention of sudden cardiac death, including risk stratification, clinical trials, CRT-D efficacy, and cost-effectiveness.
Reinforces ICDs for primary SCD prevention; leaves open refinements in risk stratification and cost-effectiveness.
Despite substantial advances in prevention and treatment of cardiovascular diseases, sudden cardiac death (SCD) remains a leading cause of death in industrialized countries. Implantable cardioverter defibrillator (ICD) has been demonstrated to be an attractive option for primary prevention of SCD in high-risk patients. This review discusses the progress in the risk stratification for selecting high-risk patients, highlights the clinical trials of primary prevention for SCD, outlines the efficacy of combined use of cardiac resynchronization therapy with ICD, and analyses the cost-effectiveness issue of this device.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: